Development and validation of stability indicating assay method for mitapivat: Identification of novel hydrolytic, photolytic, and oxidative forced degradation products …
MA Bagul, Y Patil, SS Mane… - Journal of …, 2024 - Wiley Online Library
Mitapivat is a novel, first‐in‐class orally active pyruvate kinase activator approved by the US
Food and Drug Administration in 2022 for the treatment of hemolytic anemia. There is no …
Food and Drug Administration in 2022 for the treatment of hemolytic anemia. There is no …
Pharmacological Profile of FDA-Approved Orphan Drugs in the Year 2022
Abstract Purpose of Review This manuscript aimed to provide a scientific report of recently
FDA-approved orphan drugs for helping patients, researchers, clinicians, and academicians …
FDA-approved orphan drugs for helping patients, researchers, clinicians, and academicians …
Mitapivat for Acquired Pyruvate Kinase Deficiency
H Al‐Samkari - Pediatric Blood & Cancer, 2025 - Wiley Online Library
Pyruvate kinase (PK) activation is emerging as a promising treatment modality for numerous
congenital hemolytic anemias of diverse pathophysiology, and one agent, mitapivat, is …
congenital hemolytic anemias of diverse pathophysiology, and one agent, mitapivat, is …